SCHEMBL20190068

SCHEMBL20190068

C[C@@H](Cc1ccc(Br)cn1)S(=O)(=O)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.39
GBA1 P04062 1/20 0.38
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 1/20 0.33
GRM2 Q14416 1/20 0.31
MBOAT4 Q96T53 1/20 0.31
SIRT2 Q8IXJ6 1/20 0.31
LMNA P02545 1/20 0.31
RAB9A P51151 2/20 0.31
FDPS P14324 1/20 0.30
MAPT P10636 2/20 0.30
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
TP53 P04637 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
PPARG P37231 1/20 0.30
NCOA2 Q15596 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189305 1.00 APLNR (0.39) APLNRGBA1ESR1ESR2ALDH1A1
SCHEMBL20189301 1.00 APLNR (0.39) APLNRGBA1ESR1ESR2ALDH1A1
SCHEMBL21767155 0.84 APLNR (0.39) APLNRGBA1ESR1ESR2ALDH1A1
SCHEMBL20188474 0.78 APLNR (0.35) APLNRKDM4ERAB9ANPC1
SCHEMBL20188472 0.78 APLNR (0.35) APLNRKDM4ERAB9ANPC1
SCHEMBL20200283 0.78 APLNR (0.35) APLNRKDM4ERAB9ANPC1
SCHEMBL5344274 0.77 GBA1 (0.46) APLNRGBA1ESR1ESR2ALDH1A1
SCHEMBL14464977 0.74 GBA1 (0.43) GBA1ESR1ESR2ALDH1A1KDM4E
SCHEMBL30305975 0.74 GBA1 (0.43) GBA1ESR1ESR2ALDH1A1KDM4E
SCHEMBL5144435 0.74 GBA1 (0.43) GBA1ESR1ESR2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS Amgen Inc. (US) 2019-09-25 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R APLNR 13/4885GBA1 4427/4885ESR1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.